265 related articles for article (PubMed ID: 20832750)
1. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.
Post SM; Quintás-Cardama A; Pant V; Iwakuma T; Hamir A; Jackson JG; Maccio DR; Bond GL; Johnson DG; Levine AJ; Lozano G
Cancer Cell; 2010 Sep; 18(3):220-30. PubMed ID: 20832750
[TBL] [Abstract][Full Text] [Related]
2. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.
Bond GL; Hu W; Bond EE; Robins H; Lutzker SG; Arva NC; Bargonetti J; Bartel F; Taubert H; Wuerl P; Onel K; Yip L; Hwang SJ; Strong LC; Lozano G; Levine AJ
Cell; 2004 Nov; 119(5):591-602. PubMed ID: 15550242
[TBL] [Abstract][Full Text] [Related]
3. Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes.
Ortiz GJ; Li Y; Post SM; Pant V; Xiong S; Larsson CA; El-Naggar AK; Johnson DG; Lozano G
Oncogene; 2018 Jan; 37(3):332-340. PubMed ID: 28925402
[TBL] [Abstract][Full Text] [Related]
4. The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.
Knappskog S; Bjørnslett M; Myklebust LM; Huijts PE; Vreeswijk MP; Edvardsen H; Guo Y; Zhang X; Yang M; Ylisaukko-Oja SK; Alhopuro P; Arola J; Tollenaar RA; van Asperen CJ; Seynaeve C; Staalesen V; Chrisanthar R; Løkkevik E; Salvesen HB; Evans DG; Newman WG; Lin D; Aaltonen LA; Børresen-Dale AL; Tell GS; Stoltenberg C; Romundstad P; Hveem K; Lillehaug JR; Vatten L; Devilee P; Dørum A; Lønning PE
Cancer Cell; 2011 Feb; 19(2):273-82. PubMed ID: 21316605
[TBL] [Abstract][Full Text] [Related]
5. MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk.
Knappskog S; Lønning PE
Oncotarget; 2011 Mar; 2(3):251-8. PubMed ID: 21436469
[TBL] [Abstract][Full Text] [Related]
6. Association of the
Miedl H; Lebhard J; Ehart L; Schreiber M
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691044
[TBL] [Abstract][Full Text] [Related]
7. Low-dose mithramycin exerts its anticancer effect via the p53 signaling pathway and synergizes with nutlin-3 in gynecologic cancers.
Ohgami T; Kato K; Kobayashi H; Sonoda K; Inoue T; Yamaguchi S; Yoneda T; Wake N
Cancer Sci; 2010 Jun; 101(6):1387-95. PubMed ID: 20331637
[TBL] [Abstract][Full Text] [Related]
8. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells.
Hu W; Feng Z; Ma L; Wagner J; Rice JJ; Stolovitzky G; Levine AJ
Cancer Res; 2007 Mar; 67(6):2757-65. PubMed ID: 17363597
[TBL] [Abstract][Full Text] [Related]
9. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations.
Fang S; Krahe R; Lozano G; Han Y; Chen W; Post SM; Zhang B; Wilson CD; Bachinski LL; Strong LC; Amos CI
PLoS One; 2010 May; 5(5):e10813. PubMed ID: 20520810
[TBL] [Abstract][Full Text] [Related]
10. A functional polymorphism T309G in MDM2 gene promoter, intensified by Helicobacter pylori lipopolysaccharide, is associated with both an increased susceptibility and poor prognosis of gastric carcinoma in Chinese patients.
Pan X; Li Y; Feng J; Wang X; Hao B; Shi R; Zhang G
BMC Cancer; 2013 Mar; 13():126. PubMed ID: 23506213
[TBL] [Abstract][Full Text] [Related]
11. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
12. Mdmx and Mdm2: brothers in arms?
Marine JC; Jochemsen AG
Cell Cycle; 2004 Jul; 3(7):900-4. PubMed ID: 15254433
[TBL] [Abstract][Full Text] [Related]
13. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
14. The MDM2-a splice variant of MDM2 alters transformation in vitro and the tumor spectrum in both Arf- and p53-null models of tumorigenesis.
Volk EL; Fan L; Schuster K; Rehg JE; Harris LC
Mol Cancer Res; 2009 Jun; 7(6):863-9. PubMed ID: 19491200
[TBL] [Abstract][Full Text] [Related]
15. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.
Knappskog S; Trovik J; Marcickiewicz J; Tingulstad S; Staff AC; ; Romundstad P; Hveem K; Vatten L; Salvesen HB; Lønning PE
Eur J Cancer; 2012 Sep; 48(13):1988-96. PubMed ID: 22119201
[TBL] [Abstract][Full Text] [Related]
16. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
Wade M; Wahl GM
Mol Cancer Res; 2009 Jan; 7(1):1-11. PubMed ID: 19147532
[TBL] [Abstract][Full Text] [Related]
17. Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers.
Bjørnslett M; Knappskog S; Lønning PE; Dørum A
BMC Cancer; 2012 Oct; 12():454. PubMed ID: 23039163
[TBL] [Abstract][Full Text] [Related]
18. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.
Macedo GS; Vieira IA; Vianna FSL; Alemar B; Giacomazzi J; Brandalize APC; Caleffi M; Volc SM; de Campos Reis Galvão H; Palmero EI; Achatz MI; Ashton-Prolla P
Fam Cancer; 2018 Apr; 17(2):269-274. PubMed ID: 28756477
[TBL] [Abstract][Full Text] [Related]
19. MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia.
Ebid GT; Sedhom IA; El-Gammal MM; Moneer MM
Asian Pac J Cancer Prev; 2012; 13(9):4315-20. PubMed ID: 23167335
[TBL] [Abstract][Full Text] [Related]
20. MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk.
Knappskog S; Gansmo LB; Romundstad P; Bjørnslett M; Trovik J; Sommerfelt-Pettersen J; Løkkevik E; ; Tollenaar RA; Seynaeve C; Devilee P; Salvesen HB; Dørum A; Hveem K; Vatten L; Lønning PE
PLoS One; 2012; 7(4):e36263. PubMed ID: 22558411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
